D.Western Therapeutics Institute (4576) AI Stock Analysis

• Market Cap: ¥5.44B
• Dividend Yield: N/A
• Average Volume (3M): 623.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: -9.39%
• EPS Growth: 24.12%
• Country: JP
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.44
• Shares Outstanding: 54,356,712
• 10 Day Avg. Volume: 615,690
• 30 Day Avg. Volume: 623,886
• PEG Ratio: 0.11
• Price to Book (P/B): 3.21
• Price to Sales (P/S): 11.87
• P/FCF Ratio: -9.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ¥98.00 ▼(-6.67% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held down primarily by persistent losses and ongoing cash burn, which outweigh the benefit of strong gross margins and improved leverage in 2025. Technical indicators are broadly neutral with some longer-term weakness, and valuation support is limited given negative earnings and no dividend data.

Positive Factors

High gross margins

Very high gross margins (~78% in 2025, historically ~90%+) indicate attractive unit economics for the company’s products/platform. Over the medium term, strong gross margins provide structural leverage to scale revenue into higher operating profitability once R&D and SG&A stabilize.

Improving leverage

Debt-to-equity falling to ~0.42 in 2025 from ~1.09 in 2024 shows materially improved leverage and a stronger equity base. This durable capital-structure improvement reduces refinancing and solvency risk, supporting runway for development programs and potential strategic partnerships.

Reduced cash burn trend

Operating burn improving materially year-over-year signals better cost control and cash conservation. A persistent downward trend in burn extends financing runway, increases the chance of reaching development milestones without immediate dilutive raises, and strengthens negotiating leverage with partners.

Negative Factors

Persistent negative cash flow

Operating and free cash flow are negative every year shown, so the company must rely on external financing to operate. This persistent cash burn is a lasting constraint that raises dilution and financing-cost risk, limiting strategic flexibility until cash flow turns positive.

Small, volatile revenue

Small, volatile revenue reflects development-stage commercial traction and raises predictability issues. Structurally low and fluctuating top-line limits internal funding capacity, complicates scaling fixed costs, and makes multi-month planning and milestone funding dependent on external capital or partnerships.

Deep, persistent losses

Net losses exceeding revenue (net margin ~-163% in 2025) and historically negative returns on equity indicate the business is not self-funding. Sustained unprofitability is a structural headwind that requires clinical, regulatory, or commercial breakthroughs to reverse before internal capital generation becomes viable.

D.Western Therapeutics Institute Business Overview & Revenue Model

Company Description

D.Western Therapeutics Institute (4576) is a biotechnology company focused on developing innovative therapeutic solutions for various medical conditions. Operating primarily in the healthcare sector, the company specializes in research and development of biologics and small-molecule drugs aimed at treating chronic diseases, particularly in oncology and autoimmune disorders. With a commitment to advancing science and improving patient outcomes, D.Western Therapeutics Institute leverages cutting-edge technology and extensive clinical research to create effective treatment options.

How the Company Makes Money

D.Western Therapeutics Institute generates revenue primarily through the commercialization of its pharmaceutical products, which includes both direct sales and licensing agreements. The company has established key partnerships with larger pharmaceutical firms that provide upfront payments, milestone payments tied to development progress, and royalties on future sales of approved drugs. Additionally, D.Western Therapeutics Institute may receive funding through government or private grants aimed at supporting innovative research projects, further contributing to its financial stability.

D.Western Therapeutics Institute Financial Statement Overview

Summary

Financials are dominated by development-stage risk: revenue is small/volatile and the company remains deeply unprofitable with net losses exceeding revenue, alongside sustained negative operating and free cash flow (cash burn), despite improvement in 2025. The balance sheet looks healthier in 2025 with improved leverage, but negative returns and ongoing losses remain the key constraint.

Income Statement

Revenue is relatively small and volatile (down ~7.9% in 2025 after prior fluctuations), and profitability remains deeply negative. While gross margins are very strong (about 78% in 2025, historically ~90%+), operating losses are persistent and sizable, with net losses still exceeding revenue in 2025 (net margin around -163%). The key positive is that losses narrowed meaningfully in 2025 versus 2024, but the company is still far from break-even.

Balance Sheet

Leverage looks manageable in the most recent year with debt-to-equity around 0.42 in 2025 (improving sharply from ~1.09 in 2024), supported by a much higher equity base. That said, the balance sheet has been inconsistent year-to-year, and returns on equity have been strongly negative where provided (notably in 2023–2024), reflecting ongoing losses and limiting internally generated capital.

Cash Flow

Cash generation is a clear weakness: operating cash flow and free cash flow are negative every year shown, indicating continued cash burn to fund operations. The burn improved materially in 2025 versus 2024, but free cash flow remains meaningfully negative, and cash flow does not currently provide self-funding capacity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	421.06M	387.62M	471.58M	428.36M	448.10M	414.42M
Gross Profit	363.02M	301.24M	424.74M	391.70M	420.53M	394.32M
EBITDA	-1.03B	-572.35M	-1.23B	-775.59M	-390.75M	-110.03M
Net Income	-1.09B	-632.09M	-1.29B	-812.41M	-429.69M	-149.00M
Balance Sheet
Total Assets	1.51B	2.17B	1.67B	2.37B	2.96B	2.46B
Cash, Cash Equivalents and Short-Term Investments	1.05B	1.71B	1.13B	1.87B	2.33B	1.93B
Total Debt	517.95M	605.18M	797.98M	885.12M	967.69M	340.00M
Total Liabilities	628.89M	734.01M	935.58M	1.09B	1.08B	427.72M
Stockholders Equity	884.57M	1.44B	733.87M	1.28B	1.86B	2.01B
Cash Flow
Free Cash Flow	0.00	-496.54M	-1.31B	-601.76M	-364.58M	-179.21M
Operating Cash Flow	0.00	-493.79M	-1.30B	-586.82M	-354.77M	-176.31M
Investing Cash Flow	0.00	-2.45M	-10.01M	-15.25M	-139.89M	-111.15M
Financing Cash Flow	0.00	1.08B	567.63M	134.47M	867.30M	-104.46M

D.Western Therapeutics Institute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 105.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 105 is above the 20-day moving average (MA) of 100.65, above the 50-day MA of 100.32, and below the 200-day MA of 109.42, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 27.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.

D.Western Therapeutics Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	56 Neutral	¥16.77B	120.78	―	―	1.24%	-33.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥56.70B	-13.30	―	―	-82.33%	47.73%
7776	49 Neutral	¥13.62B	-8.14	―	―	-42.49%	-2.37%
4592	48 Neutral	¥161.92B	-71.11	-636.97%	―	―	-12.69%
4576	46 Neutral	¥5.44B	-7.28	-86.84%	―	-9.39%	24.12%
4599	43 Neutral	¥18.62B	-8.15	―	―	―	11.34%

D.Western Therapeutics Institute Corporate Events

D.Western Therapeutics Narrows Loss but Warns of Deeper Red Ink in 2026

D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, but significantly narrowed its net loss to ¥632 million from ¥1,290 million a year earlier, as operating cash outflows shrank and equity and net assets improved. The company ended the period with total assets of ¥2,169 million, a stronger equity ratio of 66.1%, cash and cash equivalents of ¥1,709 million, no dividends, and it forecasts further lower sales and a deeper loss in 2026, signaling continued investment-heavy operations and an extended path to profitability for shareholders.

Despite the improvement in capital position, D.Western Therapeutics Institute projects fiscal 2026 net sales of ¥300 million, down 22.6% year on year, and a wider net loss of ¥800 million, indicating expectations of higher costs or slower revenue recognition. The absence of dividends for 2025 and in the 2026 forecast underlines management’s focus on funding R&D and maintaining liquidity, which may weigh on short-term investor returns even as the balance sheet shows increased cash and strengthened equity.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

D. Western Therapeutics Outlines FY12/25 Results and FY12/26 Outlook

D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and forecasts for the next fiscal year. The document signals continued development of its therapeutic drug portfolio and provides stakeholders with an overview of performance trends and expectations for FY12/26, positioning the company within its specialty pharma niche despite limited disclosed detail.

The materials also include a reference business overview, indicating an effort to clarify the company’s operating model and strategic direction for investors. While specific figures are not provided in the excerpt, the structure of the briefing suggests a focus on linking financial performance with pipeline advancement and future outlook, underscoring the importance of ongoing R&D to its long-term growth strategy.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

D.Western Therapeutics Narrows Losses but Forecasts Deeper Red Ink in 2026

D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, although its net loss narrowed to ¥632 million from ¥1,290 million a year earlier. The company’s equity ratio improved significantly from 43.9% to 66.1%, supported by a stronger net asset position and an increase in cash and cash equivalents to ¥1,709 million.

Operating cash outflows shrank compared with the prior year while financing cash inflows rose, indicating continued reliance on external funding to support R&D activities. For 2026, the company projects a further drop in net sales to ¥300 million and a deeper loss of ¥800 million, and it has again ruled out dividends, underscoring an ongoing investment phase and limited near-term returns for shareholders.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

D. Western Therapeutics Institute Outlines FY2025 Results and FY2026 Outlook

D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and its forecast for fiscal 2026. The document signals continued efforts to communicate performance and strategic direction, providing stakeholders with an overview of current operations and expectations for the coming year, although specific financial figures and project details are not disclosed in this summary.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

DWTI’s Glaucoma Combination Eye Drop GLA-ALPHA Debuts in Singapore Through Kowa

D. Western Therapeutics Institute announced that its partner Kowa has begun sales in Singapore of GLA-ALPHA Combination Ophthalmic Solution, a fixed-dose eye drop that combines the company’s in-house discovered Rho-kinase inhibitor ripasudil hydrochloride hydrate with brimonidine tartrate for the treatment of glaucoma and ocular hypertension. The product, already launched in Japan, Thailand and Malaysia, offers a novel mechanism versus existing combination therapies, is expected to support better intraocular pressure control and adherence for patients using multiple eye medications, and will generate royalty income for DWTI, with the financial impact to be incorporated into its earnings forecast for the year ending December 2026.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.

D. Western Therapeutics Expands Global Reach with New Ophthalmic Solution in Malaysia

D. Western Therapeutics Institute, Inc. has announced the launch of its new glaucoma and ocular hypertension treatment, ‘GLA-ALPHA® Combination Ophthalmic Solution,’ in Malaysia through its partner Kowa Co., Ltd. This product, which combines ripasudil hydrochloride hydrate and brimonidine tartrate, offers a novel treatment option with a unique mechanism of action, potentially improving patient adherence to multiple ophthalmic medications. The drug has been successfully marketed in Japan and Thailand, with plans for further expansion in Singapore and beyond. Although the launch is expected to enhance treatment options in Malaysia, it will have a minimal impact on the company’s current fiscal year earnings.

The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.